Idiopathic Parkinson disease
There are 7 papers on idiopathic Parkinson disease in aging research: 4 trials and 3 observational studies in people.
7 papers study it10 more mention it2 findings
“the peak of mediolateral trunk acceleration was significantly reduced compared to healthy controls (p < 0.05) in subjects with iPD with and without FOG”
- Human trial4
- Humans3
Associations
2Peak mediolateral trunk acceleration
downin humans1
1 study
Peak mediolateral trunk acceleration
downin humans1
Idiopathic Parkinson disease is associated with peak mediolateral trunk acceleration in humans.
“the peak of mediolateral trunk acceleration was significantly reduced compared to healthy controls (p < 0.05) in subjects with iPD with and without FOG”
HumansIdiopathic Parkinson's disease with or without freezing of gait, compared with healthy controls
Frontiers in neurology
Cancer
downin humans1
1 study
Cancer
downin humans1
Idiopathic Parkinson disease lowers the risk of cancer in idiopathic Parkinson's disease.
“In IPD, the overall risk of malignancy is reduced.”
Reviewin idiopathic Parkinson's disease
Medical hypotheses
Trial sponsors
Orion Corporation, Orion Pharma
Company1 trialPhase 4223 people
Company1 trialPhase 4151 people
Company4 trialsPhase 31,109 people
Company2 trialsPhase 3376 people
Company1 trialPhase 2150 people
Company1 trialPhase 221 people
Company1 trialPhase 1/224 people
Company1 trialPhase 132 people
Funding
1 grant since 2024National Institute of Neurological Disorders and StrokeUS$686.3k